移植肾失功后透析:瑞士经验
基于瑞士移植队列研究,纳入2008年5月至2014年12月接受肾移植的患者,分析移植肾失功后透析的实践与结局。失功后30、90、365天患者生存率分别为86%、81%、74%,92%开始血液透析,62%使用永久血管通路,后者与死亡率降低相关(HR=0.28)。
要点
- 使用永久血管通路开始血透与死亡率降低相关(HR=0.28)。
- 早期失功组1年内肾切除比例77.5%,晚期组43.2%。
核心结论
- 移植肾失功后患者死亡率高,肾切除和再移植比例高;使用导管开始血透者死亡率显著高于永久通路者。
研究设计与样本
- 基于瑞士移植队列研究的回顾性队列分析,纳入2008年5月至2014年12月接受肾移植的患者共1502例,其中77例移植肾失功。
主要发现
- 失功后30、90、365天患者生存率分别为86%、81%、74%。
- 92%开始血液透析,62%使用永久血管通路,后者与死亡率降低相关(HR=0.28)。
- 失功1年后,早期失功组77.5%(31/40)和晚期失功组43.2%(16/37)行肾切除术。
- 失功3年后,早期失功组36%和晚期失功组12%接受再次移植。
临床怎么用
- 移植肾失功后应优先考虑使用永久血管通路开始血液透析,以降低死亡风险。
- 需关注失功后早期高死亡率,加强监护。
- 免疫抑制减量和肾切除术对死亡率和再移植的作用需进一步评估。
局限性
- 回顾性队列研究,样本量较小(77例失功),可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients returning to dialysis after graft loss have high early morbidity and mortality. METHODS: We used data from the Swiss Transplant Cohort Study to describe the current practice and outcomes in Switzerland. All patients who received a renal allograft between May 2008 and December 2014 were included. The patients with graft loss were divided into two groups depending on whether the graft loss occurred within 1 year after transplantation (early graft loss group) or later (late graft loss group). Patients with primary non-function who never gained graft function were excluded. RESULTS: Seventy-seven out of 1502 patients lost their graft during follow-up, 40 within 1 year after transplantation. Eleven patients died within 30 days after allograft loss. Patient survival was 86, 81 and 74% at 30, 90 and 365 days after graft loss, respectively. About 92% started haemodialysis, 62% with definitive vascular access, which was associated with decreased mortality (hazard ratio = 0.28). At the time of graft loss, most patients were on triple immunosuppressive therapy with significant reduction after nephrectomy. One year after graft loss, 77.5% (31 of 40) of patients in the early and 43.2% (16 out of 37) in the late-loss group had undergone nephrectomy. Three years after graft loss, 36% of the patients with early and 12% with late graft loss received another allograft. CONCLUSION: In summary, our data illustrate high mortality, and a high number of allograft nephrectomies and re-transplantations. Patients commencing haemodialysis with a catheter had significantly higher mortality than patients with definitive access. The role of immunosuppression reduction and allograft nephrectomy as interdependent factors for mortality and re-transplantation needs further evaluation.
引用
- Bonani M, Achermann R, Seeger H, et al. Dialysis after graft loss: a Swiss experience. Nephrol Dial Transplant. 2020. PMID: 32170950. doi:10.1093/ndt/gfaa037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。